emtricitabine has been researched along with Vaginosis, Bacterial in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Abdool Karim, Q; Abdool Karim, SS; Archary, D; Elsherbini, JA; Kwon, DS; Lewis, L; Mansoor, LE; Mazibuko-Motau, N; Mtshali, A; Mzobe, G; Ngcapu, S; Ntuli, L; San, JE; Sobia, P; Xu, J | 1 |
Baeten, JM; Balkus, JE; Bukusi, E; Celum, C; Cohen, CR; Donnell, D; Fiedler, T; Fredricks, DN; Heffron, R; Kiarie, J; Lingappa, J; McClelland, RS; Mugo, N; Munch, M | 1 |
1 trial(s) available for emtricitabine and Vaginosis, Bacterial
Article | Year |
---|---|
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.
Topics: Adult; Anti-HIV Agents; Dysbiosis; Emtricitabine; Female; Gardnerella vaginalis; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kenya; Microbiota; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Partners; Tenofovir; Uganda; Vagina; Vaginosis, Bacterial | 2017 |
1 other study(ies) available for emtricitabine and Vaginosis, Bacterial
Article | Year |
---|---|
Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women.
Topics: Anti-Bacterial Agents; Cross-Sectional Studies; Emtricitabine; Female; HIV Infections; Humans; Pre-Exposure Prophylaxis; South Africa; Tenofovir; Vagina; Vaginosis, Bacterial | 2022 |